Form 4: Disc Medicine Director Mona Ashiya Reports Stock Sales

Director Mona Ashiya reports the sale of Disc Medicine (IRON) shares held indirectly through OrbiMed investment partnerships.

Summary

• Mona Ashiya, a director of Disc Medicine, Inc. (IRON), filed a Form 4 disclosing multiple sales of common stock.
• The sales occurred between March 19, 2025, and March 21, 2025.
• The sales were executed at prices around $54.01 and $54.02 per share.
• The shares sold were held indirectly through various OrbiMed investment partnerships: OrbiMed Private Investments VI, LP (OPI VI), OrbiMed Private Investments VIII, LP (OPI VIII), and OrbiMed Genesis Master Fund, L.P. (Genesis).
• Ashiya, along with OrbiMed Advisors, GP VIII, GP VI, and Genesis GP, disclaims beneficial ownership of the securities except to the extent of their pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a routine disclosure of stock sales by a director; the sales themselves don't necessarily indicate a positive or negative outlook.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders.

Stakeholder Impact

• The stock sales by a director could potentially influence investor sentiment, although the impact is likely to be minimal given the indirect nature of the holdings and the disclaimer of beneficial ownership.

Key Dates

Keywords

Form 4, Insider Trading, Stock Sales, Mona Ashiya, Disc Medicine, IRON, OrbiMed